Markets

AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study

Aug 3, 2026 · 08:41 AM ET· updated 3h ago

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone

Why It Matters

AIM ImmunoTech finished giving its experimental medicine Ampligen to all patients in a study testing if it helps with pancreatic cancer. This is an important checkpoint, but we won't know if the medicine actually works until doctors review all the results.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

AIM0.26

+0.01 (+2.13%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.